CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognost ic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8 Interventions: Drug: Docetaxel; Procedure: Lumpectomy; Procedure: Mastectomy; Drug: Nab-paclitaxel; Drug: Paclitaxel; Biological: Pertuzumab; Radiation: Radiation Therapy; Biological: Trastuzumab; Biological: Trastuzumab Emtansine Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Breast Lumpectomy | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Herceptin | Lumpectomy | Mastectomy | Research | Taxotere